Dermata Therapeutics increases equity plan share reserve to 402,214 shares

Dermata Therapeutics' board approved a fourth amendment to its 2021 Omnibus Equity Incentive Plan, increasing the maximum aggregate shares reserved for issuance from 153,586 to 402,214 shares, subject to stockholder approval within 12 months. The expansion provides additional capacity for employee equity compensation and incentive grants.